<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055340</url>
  </required_header>
  <id_info>
    <org_study_id>0000-159</org_study_id>
    <secondary_id>159</secondary_id>
    <secondary_id>2010_506</secondary_id>
    <nct_id>NCT01055340</nct_id>
  </id_info>
  <brief_title>A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED)</brief_title>
  <official_title>A Randomized Clinical Trial to Study Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypotheses that a single dose of oxyntomodulin (OXM) will be neutral
      or better than placebo in lowering ambient glucose levels during a graded glucose infusion
      (GGI) and that a single dose of OXM will lead to a statistically significant increase in the
      sum of the plasma βOHB + AcAc levels compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ambient plasma glucose concentration during the GGI</measure>
    <time_frame>Last 160 minutes of OXM/placebo infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma βOHB + AcAc concentrations</measure>
    <time_frame>First 300 minutes of OXM/placebo infusion</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min - Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OXM 0.6 pmol/kg/min - Placebo - OXM 3.0 pmol/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo - OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OXM 3.0 pmol/kg/min - Placebo - OXM 0.6 pmol/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo - OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min - Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxyntomodulin (OXM)</intervention_name>
    <description>Single infusion of OXM 3.0 pmol/kg/min by IV</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_label>Treatment sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Oxyntomodulin (OXM)</intervention_name>
    <description>Single infusion of OXM 0.6 pmol/kg/min by IV</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_label>Treatment sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo [ hemaccel-containing saline]</intervention_name>
    <description>Single Placebo infusion of hemaccel-containing saline by IV</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_label>Treatment sequence 3</arm_group_label>
    <arm_group_label>Treatment sequence 4</arm_group_label>
    <arm_group_label>Treatment sequence 5</arm_group_label>
    <arm_group_label>Treatment sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is judged to be in good health based on medical history, physical examination,
             and laboratory safety tests

          -  Subject has a Body Mass Index of ≥27 kg/m^2 and ≤35 kg/m^2 and weighs ≥70 kg at the
             prestudy (screening) visit

          -  Subject has been a nonsmoker and/or has not used nicotine or nicotine-containing
             products for at least approximately 6 months

          -  Subject is willing to avoid strenuous physical activity (weight lifting, running,
             bicycling, etc.) for the duration of the study

        Exclusion Criteria:

          -  Subject is mentally or legally incapacitated, has significant emotional problems at
             the time of prestudy (screening) visit

          -  Subject has a history of stroke, chronic seizures, or major neurological disorder

          -  Subject has a history of clinically significant endocrine, gastrointestinal,
             cardiovascular, hematological, hepatic, immunological, renal, respiratory, or
             genitourinary abnormalities or diseases

          -  Subject has irritable bowel disease, or recurrent occurrences of nausea, vomiting,
             diarrhea, or abdominal pain

          -  Subject has a history of hypertension requiring treatment

          -  Subject has a history of cancer

          -  Subject has history of diabetes, or family history of diabetes mellitus

          -  Subject has a history of hypersensitivity to OXM or hemaccel
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2010</study_first_submitted>
  <study_first_submitted_qc>January 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2010</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketogenesis</keyword>
  <keyword>Glucose-Dependent Insulin Secretion</keyword>
  <keyword>Graded Glucose Infusion</keyword>
  <keyword>Oxyntomodulin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

